



UNIVERSITÀ POLITECNICA DELLE MARCHE  
Repository ISTITUZIONALE

Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases

This is the peer reviewed version of the following article:

*Original*

Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases / Ursini, F.; Ruscitti, P.; Raimondo, V.; De Angelis, R.; Cacciapaglia, F.; Pigatto, E.; Olivo, D.; Di Cola, I.; Galluccio, F.; Francioso, F.; Foti, R.; Tavoni, A.; D'Angelo, S.; Campochiaro, C.; Motta, F.; De Santis, M.; Bilia, S.; Bruno, C.; De Luca, G.; Visentini, M.; Ciaffi, J.; Mancarella, L.; Brusi, V.; D'Onghia, M.; Cuomo, G.; Fusaro, E.; Dagna, L.; Guiducci, S.; Meliconi, R.; Iannone, F.; Iagnocco, A.; Giacomelli, R.; Ferri, C.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 81:3(2022), pp. 440-441. [[DOI:10.1136/annrheumdis-2021-221587](https://doi.org/10.1136/annrheumdis-2021-221587)]  
This version is available at: 11566/299362 since: 2024-09-17T12:52:49Z

*Publisher:*

*Published*

DOI:10.1136/annrheumdis-2021-221587

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. The use of copyrighted works requires the consent of the rights' holder (author or publisher). Works made available under a Creative Commons license or a Publisher's custom-made license can be used according to the terms and conditions contained therein. See editor's website for further information and terms and conditions.

This item was downloaded from IRIS Università Politecnica delle Marche (<https://iris.univpm.it>). When citing, please refer to the published version.

(Article begins on next page)



## **Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccines administration: a report of 66 cases**

**Prof. Francesco Ursini**, Rheumatology Unit, *IRCCS Istituto Ortopedico Rizzoli*, Bologna, Italy & Department of Biomedical and Neuromotor Sciences, *Alma Mater Studiorum University of Bologna*, Bologna, Italy (francesco.ursini2@unibo.it)

**Dr. Piero Ruscitti**, Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, *Università degli Studi dell'Aquila*, L'Aquila, Italy (piero.ruscitti@univaq.it)

**Dr. Vincenzo Raimondo**, Rheumatology Unit, *Rheumatology Hospital "Madonna dello Scoglio"*, Cotronei, Italy (vincenzoraimondo@hotmail.it)

**Dr. Rossella De Angelis**, Rheumatology Clinic, *Università Politecnica delle Marche*, Jesi, Italy (deaross65@libero.it)

**Dr. Fabio Cacciapaglia**, Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), *Università degli Studi di Bari Aldo Moro*, Bari, Italy (fabio.cacciapaglia79@gmail.com)

**Dr. Erika Pigatto**, Rheumatology Outpatient Clinic, *Villa Salus Hospital*, Mestre, Italy (erika.pigatto@gmail.com)

**Dr. Domenico Olivo**, Rheumatology Outpatient Clinic, *San Giovanni di Dio Hospital*, Crotone, Italy (olivod@libero.it)

**Dr. Ilenia Di Cola**, Department of Biotechnological and Applied Clinical Sciences, *Università degli Studi dell'Aquila*, L'Aquila, Italy (ileniadicola@gmail.com)

**Dr. Felice Galluccio**, Department of Rheumatology, *Azienda Ospedaliero Universitaria Careggi*, Firenze, Italy (felicegalluccio@gmail.com)

**Dr. Francesca Francioso**, Rheumatology Clinic, *Università Politecnica delle Marche*, Jesi, Italy (francioso\_francesca@libero.it)

**Dr. Rosario Foti**, Rheumatology Unit, *Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele*, Catania, Italy (rosfoti5@gmail.com)

**Dr. Antonio Gaetano Tavoni**, Department of Clinical Immunology, *University of Pisa*, Pisa, Italy (a.tavoni@med.unipi.it)

**Dr. Salvatore D'Angelo**, Rheumatology Institute of Lucania (IReL) - Rheumatology Department of Lucania, *Regional Hospital San Carlo*, Potenza, Italy (salvatore.dangelo@ospedalesancarlo.it)

**Dr. Corrado Campochiaro**, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), *IRCCS Ospedale San Raffaele*, Milan, Italy (campochiaro.corrado@hsr.it)

**Dr. Francesca Motta**, Division of Rheumatology and Clinical Immunology, *IRCCS Humanitas Research Hospital*, Italy (francesca.motta2@humanitas.it)

**Dr. Maria De Santis**, Division of Rheumatology and Clinical Immunology, *IRCCS Humanitas Research Hospital*, Rozzano, Italy (maria.de\_santis@humanitas.it)

**Dr. Silvia Bilia**, Department of Clinical Immunology, *University of Pisa*, Pisa, Italy; (silvia.bilia17@gmail.com)

**Dr. Caterina Bruno**, Rheumatology Outpatient Clinic, *Azienda Ospedaliera Pugliese Ciaccio*, Catanzaro, Italy (caterina-bruno@libero.it)

**Dr. Giacomo De Luca**, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), *IRCCS Ospedale San Raffaele*, Milan, Italy (deluca.giacomo@hsr.it)

**Dr. Marcella Visentini**, Department of Translational and Precision Medicine, *University of Rome La Sapienza*, Rome, Italy (marcella.visentini@uniroma1.it)

**Dr. Jacopo Ciaffi**, Rheumatology Unit, *IRCCS Istituto Ortopedico Rizzoli*, Bologna, Italy (jacopo.ciaffi@ior.it)

**Dr. Luana Mancarella**, Rheumatology Unit, *IRCCS Istituto Ortopedico Rizzoli*, Bologna, Italy (luana.mancarella@ior.it)

**Dr. Veronica Brusi**, Rheumatology Unit, *IRCCS Istituto Ortopedico Rizzoli*, Bologna, Italy (veronica.brusi@ior.it)

**Dr. Martina D'Onghia**, Rheumatology Unit, *IRCCS Istituto Ortopedico Rizzoli*, Bologna, Italy (martina.donghia@gmail.com)

**Dr. Giovanna Cuomo**, Clinical Immunology Outpatient Clinic, Department of Medicine, *University of Campania Luigi Vanvitelli*, Napoli, Italy (giovanna.cuomo@unicampania.it)

**Dr. Enrico Fusaro**, Rheumatology Unit, *Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino*, Torino, Italy (fusaro.reumatorino@gmail.com)

**Prof. Lorenzo Dagna**, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), *IRCCS Ospedale San Raffaele*, Milan, Italy (dagna.lorenzo@univr.it)

**Prof. Serena Guiducci**, Department of Rheumatology, *Azienda Ospedaliero Universitaria Careggi*, Firenze, Italy (s.guiducci@hotmail.com)

**Prof. Riccardo Meliconi**, Rheumatology Unit, *IRCCS Istituto Ortopedico Rizzoli*, Bologna, Italy & Department of Biomedical and Neuromotor Sciences, *Alma Mater Studiorum University of Bologna*, Bologna, Italy (riccardo.meliconi@ior.it)

**Prof. Florenzo Iannone**, Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), *Università degli Studi di Bari Aldo Moro*, Bari, Italy (florenzo.iannone@uniba.it)

**Prof. Annamaria Iagnocco**, Academic Rheumatology Centre, MFRU and Dipartimento Scienze Cliniche e Biologiche, *Università degli Studi di Torino*, Torino, Italy; (annamaria.iagnocco1@gmail.com)

**Prof. Roberto Giacomelli**, Unit of Allergology, Immunology, Rheumatology, Department of Medicine, *Campus Bio-Medico University Hospital*, Roma, Italy (r.giacomelli@unicampus.it)

**Prof. Clodoveo Ferri\***, Rheumatology Unit, *University of Modena and Reggio Emilia*, Modena, Italy & Rheumatology Unit, *Rheumatology Hospital "Madonna dello Scoglio"*, Cotronei, Italy (clferri@unimore.it)

\*Corresponding author

In the last months, mass vaccination represented the turning point of the global battle against the COVID-19 pandemic, an unprecedented challenge for physicians, healthcare professionals, health systems and pharmaceutical companies. More than 6 billion doses of vaccine have been administered to date, covering nearly 50% of the world's population. Although the vaccination campaign is still thwarted by spread of fake news disseminated by a ubiquitous anti-vaxxer movement, accumulating real-life data [1] confirm the favourable safety profile already demonstrated in phase III clinical trials [2].

Despite the lack of a steady literature evidence [3], the potential role of vaccines in promoting autoimmunity continues to intrigue many researchers. The theoretical basis of this association relies on the possible molecular mimicry between macromolecular components of the vaccine and specific human proteins and the exuberant immune response elicited by adjuvants contained in vaccines [4].

Adverse events (AEs) associated with COVID-19 vaccines are usually mild and mainly restricted to injection site reactions. Interestingly, amongst systemic AEs, arthralgia is one of the most common [2]. To the best of our knowledge, only isolated cases [5] of arthritis developed after COVID-19 vaccine administration have been described; however, in a recently published survey including 1377 participants with rheumatic diseases, 11% of the respondents reported flare requiring treatment following injection of mRNA-based vaccines [6].

The “COVID-19 and autoimmune systemic diseases” is a collaborative network of Italian rheumatologists, equally distributed across the country, spontaneously born in response to the COVID-19 pandemic with the aim to contribute to the advancing knowledge about COVID-19 and rheumatic diseases, by providing real-life data obtained from participating centres. To date, more than 60 rheumatologists from 40 different rheumatology clinics are affiliated to the study group.

In December 2020, we published a web-based survey form and invited all members of the study group to inform cases of inflammatory musculoskeletal manifestations (e.g., synovitis, tenosynovitis, enthesitis, inflammatory spinal pain or girdles pain/stiffness with serological evidence of inflammation) with onset within four weeks from the administration of the first or second dose of one of the COVID-19 vaccines approved in Italy (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S), prospectively encountered during routine clinical practice since the beginning of the vaccination campaign, in January 2021, and up to August 31, 2021. Exclusion criteria were a past history of any inflammatory rheumatic disease, isolated arthralgia/myalgia without clear evidence of inflammation or vague and/or non-specific musculoskeletal complains. Written informed consent was obtained from all patients.

By using this approach, we built a case series comprising 66 individual patients reported by 16 different rheumatology centres; most of them (59%) received the BNT162b2 vaccine. The average delay between the day of the “trigger” injection (44.4% coinciding with the first dose) and arthritis onset was 11-13 days.

Stratification according to the predominant pattern of involvement at presentation (Table 1) revealed that girdles pain/stiffness with acute phase reactants elevation resembling polymyalgia rheumatica (PMR-like) was the most common (41%) clinical picture followed by oligoarthritis (32%) and polyarthritis (27%). Polyarticular and PMR-like cases were mainly symmetric (83% and 89% respectively); involvement of small joints and tenosynovitis (39%) were significantly more frequent in polyarthritic forms (61% and 39%, respectively) while

enthesitis was more common in oligoarthritic presentation (14%). Of note, two patients (one in the polyarticular and one in the oligoarticular group, respectively) had also inflammatory back pain with evidence of active sacroiliitis and/or spondylitis on magnetic resonance (MR) imaging. Detection of autoantibodies in sera was an uncommon finding; HLA-B27 status was obtained in only 21 (31.8%) patients of which one in the polyarthritis subgroup tested positive.

Most patients were treated with glucocorticoids (50-78%), non-steroidal anti-inflammatory drugs (NSAIDs) (33-52%) or analgesics (14-28%) while disease-modifying antirheumatic drugs (DMARDs) were used in five (28%) patients with polyarthritis, five (24%) patients with oligoarthritis and only three (11%) patients with PMR-like presentation.

Despite the limitation of a very short follow-up, the clinical course seemed excellent in patients with PMR-like onset with 74% achieving full remission of symptoms after two weeks; on the other hand, 67% of patients with polyarthritis had active disease after an average follow-up of six weeks.

In conclusion, despite a clear cause-effect relationship is far to be ascertained, our data suggest that inflammatory musculoskeletal symptoms may occasionally develop in close temporal association with COVID-19 vaccine administration. However, even assuming a direct causal relationship, we feel that the overall safety of COVID-19 vaccines remains unaffected and the benefits of vaccination largely outweigh the minimal risks associated with such uncommon inflammatory complications, probably reflecting a transient reactogenic response to the vaccine rather than a structured, chronic inflammatory joint disease.

## References

1. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *The New England journal of medicine*. 2021 Sep 16; 385(12):1078-1090.
2. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Vaccines*. 2021 May 6; 9(5).
3. Petras M, Lesna IK, Danova J, Celko AM. Can Vaccination Trigger Autoimmune Disorders? A Meta-Analysis. *Vaccines*. 2021 Jul 25; 9(8).
4. Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. *Cellular & molecular immunology*. 2018 Jun; 15(6):586-594.
5. An QJ, Qin DA, Pei JX. Reactive arthritis after COVID-19 vaccination. *Human vaccines & immunotherapeutics*. 2021 Sep 2; 17(9):2954-2956.
6. Connolly CM, Ruddy JA, Boyarsky BJ, Barbur I, Werbel WA, Geetha D, et al. Disease Flare and Reactogenicity in Patients with Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. *Arthritis & rheumatology*. 2021 Aug 4.

## Acknowledgments

None

## Competing Interests

None

### **Funding**

None

### **Patient and Public Involvement statement**

Patients or public were not involved because the current manuscript is only the description of a case series.



**Table 1.** Clinical features of the patients stratified according to the pattern of presentation.

	<b>Polyarthritits (n = 18)</b>	<b>Oligoarthritis (n = 21)</b>	<b>PMR-like (n = 27)</b>	<b>p value</b>
<b>Age, years</b>	54 ± 16	64 ± 15	67 ± 10	<b>0.006</b>
<b>Female gender, n (%)</b>	10 (55.6)	16 (76.2)	17 (63.0)	0.696
<b>Past COVID-19, n (%)</b>	2 (11.1)	1 (4.8)	0 (0.0)	0.211
<b>Specific vaccine administered</b>				
<b>BNT162b2, n (%)</b>	9 (50.0)	12 (57.1)	18 (66.7)	0.363
<b>mRNA-1273, n (%)</b>	0 (0.0)	1 (4.8)	2 (7.4)	0.535
<b>AZD1222, n (%)</b>	9 (50.0)	7 (33.3)	7 (25.9)	0.197
<b>Ad26.COV2.S, n (%)</b>	0 (0.0)	1 (4.8)	0 (0.0)	0.295
<b>Vaccine-related adverse events</b>				
<b>None, n (%)</b>	3 (16.7)	9 (42.9)	11 (40.7)	0.195
<b>Pain at the injection site, n (%)</b>	12 (66.7)	10 (47.6)	13 (48.1)	0.440
<b>Fever, n (%)</b>	5 (27.8)	1 (4.8)	3 (11.1)	0.112
<b>Headache, n (%)</b>	2 (11.1)	2 (9.5)	2 (7.4)	0.869
<b>Fatigue, n (%)</b>	6 (33.3)	3 (14.3)	1 (3.7)	<b>0.023</b>
<b>Rheumatic manifestations onset after first dose, n (%)</b>	11 (61.1)	7 (33.3)	12 (44.4)	0.322
<b>Delay between vaccine administration and rheumatic manifestations onset, days</b>	12 ± 9	11 ± 7	13 ± 7	0.450
<b>Rheumatic manifestations</b>				
<b>Symmetrical involvement, n (%)</b>	15 (83.3)	9 (42.9)	24 (88.9)	<b>0.001</b>
<b>Involvement of small joints, n (%)</b>	11 (61.1)	4 (19.0)	2 (7.4)	<b>&lt; 0.001</b>

Tenosynovitis, n (%)	7 (38.9)	4 (19.0)	2 (7.4)	<b>0.029</b>
Enthesitis, n (%)	0 (0.0)	3 (14.3)	0 (0.0)	<b>0.023</b>
Bursitis, n (%)	1 (5.6)	1 (4.8)	0 (0.0)	0.456
Inflammatory back pain with MRI evidence of sacroiliitis or spondylitis, n (%)	1 (5.6)	1 (4.8)	0 (0.0)	0.456
Fatigue, n (%)	4 (22.2)	3 (14.3)	8 (29.6)	0.613
<b>Laboratory features</b>				
ESR, mm/h	51 ± 34	36 ± 25	45 ± 28	0.108
CRP, mg/dL	2.13 (1.25 – 5.20)	1.90 (0.50 – 3.61)	2.13 (1.25 – 5.20)	0.121
RF positive, n (%)*	1 (6.3)	0 (0.0)	0 (0.0)	0.255
ACPA positive, n (%)*	1 (6.3)	0 (0.0)	0 (0.0)	0.255
RF and ACPA positive, n (%)*	1 (6.3)	0 (0.0)	0 (0.0)	0.255
ANA positive, n (%)#	2 (15.4)	3 (17.6)	0 (0.0)	0.061
<b>Treatment</b>				
NSAIDs, n (%)	6 (33.3)	11 (52.4)	9 (33.3)	0.507
Paracetamol or opioids, n (%)	5 (27.8)	3 (14.3)	6 (22.2)	0.669
Glucocorticoids, n (%)	9 (50.0)	13 (61.9)	21 (77.8)	0.113
Methotrexate, n (%)	4 (22.2)	5 (23.8)	3 (11.1)	0.490
Sulfasalazine, n (%)	1 (5.6)	0 (0.0)	0 (0.0)	0.523
Follow-up duration, weeks	6 (2 – 8)	4 (3 – 8)	2 (1 – 5)	0.209
<b>Outcome</b>				
Active disease, n (%)	12 (66.7)	9 (42.9)	6 (22.2)	<b>0.007</b>
Remission, n (%)	6 (33.3)	10 (47.6)	20 (74.1)	<b>0.014</b>
N/A, n (%)	0 (0.0)	2 (9.5)	1 (3.7)	0.296

Data are expressed as mean  $\pm$  standard deviation (SD) or median (25<sup>th</sup> – 75<sup>th</sup> percentile), as appropriate. P values refer to one-way analysis of variance (ANOVA) or Kruskal-Wallis H test for continuous or categorical variables, respectively.

**Legend:** ACPA, anti-citrullinated protein antibodies; ANA, antinuclear antibodies; COVID-19, Coronavirus disease 2019; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MRI, magnetic resonance imaging; NSAIDs, non-steroidal anti-inflammatory drugs; N/A, not available; PMR, polymyalgia rheumatica; RF, rheumatoid factor.

\* Information for RF/ACPA status available for 56 patients

# Information for ANA status available for 48 patients